Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6409) 6409
Book Review (2125) 2125
Publication (662) 662
Book Chapter (48) 48
Conference Proceeding (18) 18
Reference (6) 6
Dissertation (4) 4
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5241) 5241
glucagon-like peptide-1 (4322) 4322
humans (3641) 3641
animals (2923) 2923
endocrinology & metabolism (2281) 2281
male (2003) 2003
type 2 diabetes (1707) 1707
diabetes (1684) 1684
diabetes mellitus, type 2 - drug therapy (1635) 1635
glucose (1319) 1319
glucagon (1279) 1279
hypoglycemic agents - therapeutic use (1244) 1244
glucagon-like peptide-1 receptor (1235) 1235
insulin (1221) 1221
mice (1151) 1151
pharmacology & pharmacy (1136) 1136
female (1082) 1082
glp-1 (1050) 1050
rats (1027) 1027
peptides (997) 997
liraglutide (957) 957
obesity (888) 888
glycemic control (851) 851
exenatide (759) 759
glucagon-like peptide 1 (714) 714
diabetes mellitus (711) 711
middle aged (692) 692
hypoglycemic agents - pharmacology (679) 679
peptides - pharmacology (679) 679
receptors, glucagon - agonists (677) 677
analysis (636) 636
insulin - metabolism (625) 625
blood glucose - metabolism (620) 620
physiological aspects (620) 620
glucagon-like peptide-1 receptor - agonists (607) 607
research (593) 593
glucagon-like peptide 1 - metabolism (589) 589
exendin-4 (576) 576
dextrose (570) 570
biochemistry & molecular biology (569) 569
type-2 diabetes-mellitus (556) 556
rodents (547) 547
abridged index medicus (546) 546
venoms - pharmacology (545) 545
internal medicine (532) 532
diabetes mellitus, type 2 - metabolism (529) 529
physiology (512) 512
adult (511) 511
care and treatment (504) 504
insulin secretion (499) 499
receptors, glucagon - metabolism (490) 490
secretion (490) 490
health aspects (488) 488
double-blind (487) 487
insulin resistance (482) 482
glucagon-like peptide 1 - analogs & derivatives (481) 481
diabetes mellitus, type 2 - blood (479) 479
endocrine system (476) 476
hypoglycemic agents - administration & dosage (475) 475
treatment outcome (469) 469
aged (467) 467
medicine & public health (466) 466
hypoglycemic agents (462) 462
beta-cell function (447) 447
hypoglycemic agents - adverse effects (445) 445
peptides - therapeutic use (445) 445
metformin (444) 444
blood glucose - drug effects (443) 443
food-intake (443) 443
digestive, oral, and skin physiology (442) 442
risk factors (440) 440
insulin-secretion (430) 430
drug therapy (426) 426
glucagon-like peptide 1 - pharmacology (423) 423
dipeptidyl-peptidase iv inhibitors - therapeutic use (419) 419
expression (415) 415
mice, inbred c57bl (415) 415
diabetes therapy (413) 413
hyperglycemia (406) 406
metabolism (399) 399
neurosciences (399) 399
hormones, hormone substitutes, and hormone antagonists (391) 391
receptor (386) 386
glucagon-like peptide 1 - therapeutic use (384) 384
article (380) 380
medicine, research & experimental (379) 379
glucose metabolism (375) 375
body weight (372) 372
incretin (365) 365
rats, sprague-dawley (365) 365
glucagon-like peptide-1 receptor - metabolism (354) 354
type 2 diabetes mellitus (346) 346
venoms - therapeutic use (339) 339
signal transduction (335) 335
gastric-inhibitory polypeptide (334) 334
glucose - metabolism (334) 334
insulin-secreting cells - metabolism (332) 332
review (332) 332
cell biology (325) 325
dependent insulinotropic polypeptide (324) 324
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6281) 6281
German (44) 44
Spanish (30) 30
Japanese (19) 19
French (12) 12
Korean (10) 10
Chinese (9) 9
Italian (8) 8
Czech (3) 3
Russian (3) 3
Danish (2) 2
Hungarian (2) 2
Polish (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4
by Kanoski, Scott E and Fortin, Samantha M and Arnold, Myrtha and Grill, Harvey J and Hayes, Matthew R
Endocrinology, ISSN 0013-7227, 08/2011, Volume 152, Issue 8, pp. 3103 - 3112
The long-acting glucagon-like peptide-1 receptor (GLP-1R) agonists, exendin-4 and liraglutide, suppress food intake and body weight. The mediating site(s) of... 
ENERGY-BALANCE | BODY-WEIGHT | GLUCAGON-LIKE-PEPTIDE-1 RECEPTOR | GLUCAGON-LIKE PEPTIDE-1 | RAT | DIET-INDUCED OBESE | FOOD-INTAKE | DIFFERENT MECHANISMS | ENDOCRINOLOGY & METABOLISM | VAGAL AFFERENTS | MEAL SIZE | Calcitonin - pharmacology | Receptors, Glucagon - agonists | Glucagon-Like Peptide 1 - analogs & derivatives | Appetite Depressants - pharmacology | Glucagon-Like Peptide 1 - pharmacology | Body Weight - drug effects | Rats | Male | Peptide Fragments - pharmacology | Brain - physiology | Rats, Sprague-Dawley | Peptides - pharmacology | Eating - drug effects | Vagus Nerve - physiology | Animals | Glucagon-Like Peptide-1 Receptor | Venoms - pharmacology | Liraglutide | Receptors, Glucagon - physiology | Index Medicus | Abridged Index Medicus | 500 | 300 | Energy Balance-Obesity
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes
by Hernández, Cristina and Bogdanov, Patricia and Corraliza, Lidia and García-Ramírez, Marta and Solà-Adell, Cristina and Arranz, José A and Arroba, Ana I and Valverde, Angela M and Simó, Rafael
Diabetes, ISSN 0012-1797, 01/2016, Volume 65, Issue 1, pp. 172 - 187
Retinal neurodegeneration is an early event in the pathogenesis of diabetic retinopathy (DR). Since glucagon-like peptide 1 (GLP-1) exerts neuroprotective... 
INSULIN | ALZHEIMER-DISEASE | APOPTOSIS | CELLS | EXENDIN-4 ANALOG | EARLY EVENT | ENDOCRINOLOGY & METABOLISM | RETINOPATHY | UP-REGULATION | EXPRESSION | PROTECTS | Immunohistochemistry | Retina - drug effects | Administration, Ophthalmic | Glucagon-Like Peptide 1 | Apoptosis - drug effects | Humans | Middle Aged | Male | Diabetes Mellitus, Type 2 - metabolism | Glial Fibrillary Acidic Protein - metabolism | Glucagon-Like Peptide-1 Receptor - genetics | Glucagon-Like Peptide-1 Receptor - metabolism | Neuroprotective Agents - pharmacology | Liraglutide - pharmacology | Female | Diabetes Mellitus, Experimental - complications | Diabetic Retinopathy - etiology | Retinal Neurons - drug effects | Diabetes Mellitus, Experimental - metabolism | Real-Time Polymerase Chain Reaction | Diabetes Mellitus, Type 2 - complications | Electroretinography | Blotting, Western | Peptides - pharmacology | Diabetic Retinopathy - prevention & control | Animals | Glial Fibrillary Acidic Protein - drug effects | Aged | Mice | Retinal Neurons - pathology | Venoms - pharmacology | Retina - pathology | Glucagon-Like Peptide-1 Receptor - agonists | Diabetic retinopathy | Care and treatment | Glucagon | Dosage and administration | Research | Gene expression | Insulin | Neuropeptides | Retina | Diabetes | Neurodegeneration | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
by Bjerre Knudsen, Lotte and Madsen, Lars Wichmann and Andersen, Søren and Almholt, Kasper and de Boer, Anne S and Drucker, Daniel J and Gotfredsen, Carsten and Egerod, Frederikke Lihme and Hegelund, Anne Charlotte and Jacobsen, Helene and Jacobsen, Søren Dyring and Moses, Alan C and Mølck, Anne-Marie and Nielsen, Henriette S and Nowak, Jette and Solberg, Helene and Thi, Tu D. L and Zdravkovic, Milan
Endocrinology, ISSN 0013-7227, 04/2010, Volume 151, Issue 4, pp. 1473 - 1486
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog developed for type 2 diabetes. Long-term liraglutide exposure in rodents was associated with thyroid... 
DIABETIC-PATIENTS | RET | GLP-1 | RAT | RHESUS-MONKEY | BETA-CELLS | LINE | ENDOCRINOLOGY & METABOLISM | OMEPRAZOLE | CARCINOMA | GLAND | Immunohistochemistry | Gene Expression - drug effects | Species Specificity | Humans | Diabetes Mellitus, Type 1 - metabolism | Macaca fascicularis | RNA, Messenger - metabolism | Obesity - genetics | Dose-Response Relationship, Drug | In Situ Hybridization | Radioimmunoassay | Thyroid Gland - cytology | Calcitonin - metabolism | Cyclic AMP - metabolism | Thyroid Gland - drug effects | Receptors, Glucagon - genetics | Cell Line | Enzyme-Linked Immunosorbent Assay | Glucagon-Like Peptide 1 - analogs & derivatives | RNA, Messenger - genetics | Cells, Cultured | Glucagon-Like Peptide 1 - pharmacology | Diabetes Mellitus, Type 1 - genetics | Rats | Receptors, Glucagon - metabolism | Calcitonin - genetics | Reverse Transcriptase Polymerase Chain Reaction | Rats, Sprague-Dawley | Blotting, Western | Mice, Knockout | Obesity - metabolism | Animals | Glucagon-Like Peptide-1 Receptor | Cell Proliferation - drug effects | Mice | Thyroid Gland - metabolism | Liraglutide | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
by Evers, Andreas and Haack, Torsten and Lorenz, Martin and Bossart, Martin and Elvert, Ralf and Henkel, Bernd and Stengelin, Siegfried and Kurz, Michael and Glien, Maike and Dudda, Angela and Lorenz, Katrin and Kadereit, Dieter and Wagner, Michael
Journal of Medicinal Chemistry, ISSN 0022-2623, 05/2017, Volume 60, Issue 10, pp. 4293 - 4303
Dual activation of the glucagon-like peptide 1 (GLP-1) and glucagon receptor has the potential to lead to a novel therapy principle for the treatment of... 
CONTROLLED-TRIAL | BODY-WEIGHT | IN-VITRO | CHEMISTRY, MEDICINAL | GLP-1 | LIRAGLUTIDE | ANALOG | PROTEIN-COUPLED RECEPTOR | EXENATIDE | MICE | OXYNTOMODULIN | Peptides - blood | Obesity - drug therapy | Body Weight - drug effects | Glucagon-Like Peptide-1 Receptor - chemistry | Structure-Activity Relationship | Exenatide | Hypoglycemic Agents - blood | Glucagon-Like Peptide-1 Receptor - metabolism | Glucagon-Like Peptide 1 - agonists | Swine | Drug Design | Venoms - blood | Female | Amino Acid Sequence | Blood Glucose - analysis | Glucagon-Like Peptide 1 - metabolism | Peptides - chemistry | Mice, Inbred C57BL | Glucagon-Like Peptide 1 - chemistry | Hypoglycemic Agents - chemistry | Hypoglycemic Agents - pharmacology | Obesity - metabolism | Peptides - pharmacology | Animals | Glucagon - metabolism | Mice, Obese | Molecular Docking Simulation | Venoms - pharmacology | Venoms - chemistry | Blood Glucose - metabolism | Glucagon-Like Peptide-1 Receptor - agonists | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
by Secher, Anna and Jelsing, Jacob and Baquero, Arian F and Hecksher-Sørensen, Jacob and Cowley, Michael A and Dalbøge, Louise S and Hansen, Gitte and Grove, Kevin L and Pyke, Charles and Raun, Kirsten and Schäfer, Lauge and Tang-Christensen, Mads and Verma, Saurabh and Witgen, Brent M and Vrang, Niels and Knudsen, Lotte Bjerre
Journal of Clinical Investigation, ISSN 0021-9738, 10/2014, Volume 124, Issue 10, pp. 4473 - 4488
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2 diabetes. Besides lowering blood glucose, liraglutide also reduces... 
MEDICINE, RESEARCH & EXPERIMENTAL | BODY-WEIGHT | GLUCOSE-HOMEOSTASIS | GLUCAGON-LIKE PEPTIDE-1 | FOOD-INTAKE | ANALOG LIRAGLUTIDE | CENTRAL-NERVOUS-SYSTEM | ENERGY-INTAKE | CHOROID-PLEXUS | SUBFORNICAL ORGAN | BLOOD-BRAIN-BARRIER | Vagus Nerve - metabolism | Glucagon-Like Peptide 1 - analogs & derivatives | Glucagon-Like Peptide 1 - pharmacology | Body Weight - drug effects | Electrophysiology | Rats | Receptors, Glucagon - metabolism | Male | Mice, Transgenic | Weight Loss - drug effects | Rats, Sprague-Dawley | Nerve Tissue Proteins - metabolism | Pro-Opiomelanocortin - metabolism | Animals | Hypothalamus - metabolism | Glucagon-Like Peptide-1 Receptor | Arcuate Nucleus of Hypothalamus - drug effects | Paraventricular Hypothalamic Nucleus - metabolism | Mice | Neurons - metabolism | Liraglutide | Disease Models, Animal | Neural circuitry | Medical examination | Patient outcomes | Weight loss | Physiological aspects | Hypothalamus | Observations | Obesity | Weight control | Peptides | Rodents | Software | Physiology | Food | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text GLP-1 receptor agonists, CKD, and eGFR trajectory
by van Baar, Michaël J B and van Raalte, Daniël H and Muskiet, Marcel H A
The Lancet Diabetes & Endocrinology, ISSN 2213-8587, 10/2018, Volume 6, Issue 10, pp. 764 - 765
KIDNEY | ENDOCRINOLOGY & METABOLISM | OUTCOMES | Renal Insufficiency, Chronic | Insulin Glargine | Humans | Immunoglobulin Fc Fragments | Diabetes Mellitus, Type 2 | Glucagon-Like Peptides - analogs & derivatives | Glucagon-Like Peptide-1 Receptor - agonists | Recombinant Fusion Proteins | ErbB Receptors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk: a meta‐analysis of randomized clinical trials
by Monami, M and Dicembrini, I and Nardini, C and Fiordelli, I and Mannucci, E
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 01/2014, Volume 16, Issue 1, pp. 38 - 47
AimsNew drugs for type 2 diabetes need to demonstrate their cardiovascular safety, due regulatory requirements from the Food and Drug Administration. For this... 
mortality | cardiovascular disease | GLP | meta‐analysis | 1 analogue | Cardiovascular disease | GLP-1 analogue | Mortality | Meta-analysis | LIRAGLUTIDE | SAFETY | EXENATIDE | ENDOCRINOLOGY & METABOLISM | meta-analysis | Receptors, Glucagon - agonists | Glucagon-Like Peptide 1 - administration & dosage | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Humans | Risk Factors | Male | Peptides - administration & dosage | Randomized Controlled Trials as Topic | Diabetes Mellitus, Type 2 - blood | Glucagon-Like Peptide-1 Receptor | Hypoglycemic Agents - administration & dosage | Cardiovascular Diseases - epidemiology | Venoms - administration & dosage | Female | Cardiovascular Diseases - chemically induced | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Type 2 diabetes | Glucagon | Regulatory compliance | Cardiovascular diseases | Risk factors | Cholesterol | Clinical trials | Diabetes | Drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text GLP-1 receptor agonists: differentiation within the class
by Taylor, Simeon I
The Lancet Diabetes & Endocrinology, ISSN 2213-8587, 02/2018, Volume 6, Issue 2, pp. 83 - 85
NON-INFERIORITY | METFORMIN | LIXISENATIDE | CARDIOVASCULAR OUTCOMES | EXENATIDE | ENDOCRINOLOGY & METABOLISM | ONCE-DAILY LIRAGLUTIDE | OPEN-LABEL | PHASE-3 | Hypoglycemic Agents | Glucagon-Like Peptide 1 | Glucagon-Like Peptide-1 Receptor | Venoms | Humans | Diabetes Mellitus, Type 2 | Liraglutide | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Blood pressure‐lowering effects of GLP‐1 receptor agonists exenatide and liraglutide: a meta‐analysis of clinical trials
by Wang, B and Zhong, J and Lin, H and Zhao, Z and Yan, Z and He, H and Ni, Y and Liu, D and Zhu, Z
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2013, Volume 15, Issue 8, pp. 737 - 749
Aims: Aside from lowering blood glucose, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) attract much attention because of their cardioprotective... 
randomized trials | GLP | meta‐analysis | hypertension | Hypertension | GLP-1 | Randomized trials | Meta-analysis | GLYCEMIC CONTROL | meta-analysis | WEIGHT-LOSS | ANALOG LIRAGLUTIDE | OPEN-LABEL | TWICE-DAILY EXENATIDE | DRUG-NAIVE PATIENTS | GLUCAGON-LIKE PEPTIDE-1 | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | TYPE-2 DIABETES-MELLITUS | CARDIOVASCULAR RISK-FACTORS | Cardiovascular Diseases - prevention & control | Humans | Hypertension - drug therapy | Male | Hypertension - blood | Cardiovascular Diseases - blood | Female | Blood Pressure - drug effects | Diabetic Angiopathies - prevention & control | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Glucagon-Like Peptide 1 - analogs & derivatives | Sulfonylurea Compounds - therapeutic use | Treatment Outcome | Diabetic Angiopathies - blood | Randomized Controlled Trials as Topic | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Glucagon-Like Peptide-1 Receptor | Venoms - therapeutic use | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Insulin - therapeutic use | Liraglutide | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Glucose metabolism | Peptides | Blood sugar | Blood pressure | Hypoglycemic agents | Confidence intervals | Medical research | Drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide
by Kanoski, Scott E and Rupprecht, Laura E and Fortin, Samantha M and De Jonghe, Bart C and Hayes, Matthew R
Neuropharmacology, ISSN 0028-3908, 04/2012, Volume 62, Issue 5-6, pp. 1916 - 1927
The FDA-approved glucagon-like-peptide-1 receptor (GLP-1R) agonists exendin-4 and liraglutide reduce food intake and body weight. Nausea is the most common... 
Obesity | GLP-1 | Vomiting | Malaise | Diabetes | Byetta | Victoza | Exenatide | GLYCEMIC CONTROL | RAT | FOS EXPRESSION | EXENATIDE EXENDIN-4 | OPEN-LABEL | CHEMOTHERAPY AGENT CISPLATIN | TREATED PATIENTS | INDUCED PICA | NEUROSCIENCES | GLUCAGON-LIKE PEPTIDE-1 | PHARMACOLOGY & PHARMACY | INTERIM ANALYSIS | Receptors, Glucagon - agonists | Nausea - chemically induced | Glucagon-Like Peptide 1 - analogs & derivatives | Body Weight - drug effects | Rats | Vagus Nerve - drug effects | Male | Nausea - physiopathology | Solitary Nucleus - drug effects | Rats, Sprague-Dawley | Eating - physiology | Vagus Nerve - physiopathology | Eating - drug effects | Hypoglycemic Agents - toxicity | Animals | Peptides - toxicity | Glucagon-Like Peptide-1 Receptor | Body Weight - physiology | Glucagon-Like Peptide 1 - toxicity | Liraglutide | Solitary Nucleus - physiopathology | Venoms - toxicity | Analysis | Body weight | Nausea | Index Medicus | diabetes | malaise | obesity | exenatide | vomiting
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes The T-emerge 2 trial
by Rosenstock, J and Balas, B and Charbonnel, B and Bolli, GB and Boldrin, M and Ratner, R and Balena, R and T-Emerge 2 Study Grp and T-emerge 2 Study Group and for the T-emerge 2 Study Group
DIABETES CARE, ISSN 0149-5992, 03/2013, Volume 36, Issue 3, pp. 498 - 504
OBJECTIVE - Taspoglutide is a long-acting glucagon-like peptide 1 receptor agonist developed for treatment of type 2 diabetes. The efficacy and safety of... 
METFORMIN | EFFICACY | SAFETY | TOLERABILITY | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | PEPTIDE-1 ANALOG | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Humans | Middle Aged | Male | Peptides - administration & dosage | Young Adult | Glucagon-Like Peptide-1 Receptor | Hypoglycemic Agents - administration & dosage | Adolescent | Venoms - therapeutic use | Venoms - administration & dosage | Adult | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Peptides - therapeutic use | Type 2 diabetes | Complications and side effects | Taspoglutide | Dosage and administration | Genetic aspects | Research | Drug therapy | Exenatide | Clinical trials | Diabetes | Gastrointestinal surgery | Glucose | Pharmaceutical industry | Gastrointestinal diseases | Index Medicus | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans
by Koska, J and Sands, M and Burciu, C and D'Souza, KM and Raravikar, K and Liu, J and Truran, S and Franco, DA and Schwartz, EA and Schwenke, DC and D'Alessio, D and Migrino, RQ and Reaven, PD
DIABETES, ISSN 0012-1797, 07/2015, Volume 64, Issue 7, pp. 2624 - 2635
GLP-1 receptor (GLP-1R) agonists may improve endothelial function (EF) via metabolic improvement and direct vascular action. The current study determined the... 
INSULIN | DEPENDENT DIABETES-MELLITUS | BRACHIAL-ARTERY | HYPERGLYCEMIA | GLUCAGON-LIKE PEPTIDE-1 | POSTPRANDIAL HYPERTRIGLYCERIDEMIA | ENDOCRINOLOGY & METABOLISM | SECRETION | K-ATP | CORONARY-ARTERY-DISEASE | CARDIOVASCULAR RISK-FACTORS | Receptors, Glucagon - agonists | Blood Glucose - analysis | Double-Blind Method | Humans | Cells, Cultured | Male | Peptides - pharmacology | Cross-Over Studies | AMP-Activated Protein Kinases - physiology | Diabetes Mellitus, Type 2 - physiopathology | Glucagon-Like Peptide-1 Receptor | Triglycerides - blood | Female | Venoms - pharmacology | Vasodilation - drug effects | Diabetes Mellitus, Type 2 - drug therapy | Endothelial Cells - physiology | Receptors, Glucagon - physiology | Endothelial Cells - drug effects | Tissue | Lipids | T cell receptors | Diabetes | Glucose | Diet | Index Medicus | Abridged Index Medicus | Pharmacology and Therapeutics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Safety issues with glucagon‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials
by Monami, Matteo and Nreu, Besmir and Scatena, Alessia and Cresci, Barbara and Andreozzi, Francesco and Sesti, Giorgio and Mannucci, Edoardo
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 09/2017, Volume 19, Issue 9, pp. 1233 - 1241
AimGlucagon-like peptide 1 receptor agonists (GLP1-RA) have been associated with an increased risk of pancreatitis and pancreatic cancer. Prior meta-analyses... 
GLP | 1 analogue | meta‐analysis | meta-analysis | GLP-1 analogue | POPULATION | METAANALYSIS | EXENATIDE | SITAGLIPTIN | INCRETIN-BASED THERAPIES | RISK | LIRAGLUTIDE | CLINICAL-TRIALS | ENDOCRINOLOGY & METABOLISM | REAL-WORLD DATA | ASSOCIATION | Hypoglycemic Agents - therapeutic use | Reproducibility of Results | Pancreatic Neoplasms - epidemiology | Pancreatitis - epidemiology | Humans | Pancreas - drug effects | Cholelithiasis - epidemiology | Risk | Diabetes Mellitus, Type 2 - metabolism | Pancreatitis - complications | Cholelithiasis - complications | Evidence-Based Medicine | Pancreatitis - chemically induced | Incidence | Randomized Controlled Trials as Topic | Glucagon-Like Peptide-1 Receptor - metabolism | Pancreatic Neoplasms - chemically induced | Cholelithiasis - chemically induced | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Pancreatic Neoplasms - complications | Biliary Tract - drug effects | Diabetes Mellitus, Type 2 - complications | Glucagon-Like Peptide-1 Receptor - agonists | Type 2 diabetes | Clinical trials | Glucagon | Analysis | Pancreatic cancer | Pancreatitis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the Glucagon-Like Peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: A retrospective analysis of the lifelink database
by Best, Jennie H and Hoogwerf, Byron J and Herman, William H and Pelletier, Elise M and Smith, Daniel B and Wenten, Made and Hussein, Mohamed A
Diabetes Care, ISSN 0149-5992, 01/2011, Volume 34, Issue 1, pp. 90 - 95
OBJECTIVE- To test the hypothesis that exenatide twice daily reduces the relative incidence of cardiovascular disease (CVD) events among patients with type 2... 
RECORDS | TRIALS | HYPERGLYCEMIA | METAANALYSIS | MYOCARDIAL-INFARCTION | ENDOCRINOLOGY & METABOLISM | COMPLICATIONS | DEATH | MELLITUS | OUTCOMES | ACCURACY | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - antagonists & inhibitors | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Diabetes Mellitus, Type 2 - metabolism | Peptides - administration & dosage | Glucagon-Like Peptide-1 Receptor | Hypoglycemic Agents - administration & dosage | Venoms - therapeutic use | Venoms - administration & dosage | Adult | Female | Retrospective Studies | Diabetes Mellitus, Type 2 - drug therapy | Diabetes Mellitus, Type 2 - complications | Peptides - therapeutic use | Type 2 diabetes | Stroke (Disease) | Diabetics | Peptides | Coronary artery bypass | Cardiac patients | Hypoglycemic agents | Cardiovascular diseases | Risk factors | Heart attack | Antilipemic agents | Studies | Hypertension | Health Insurance Portability & Accountability Act 1996-US | Heart attacks | Statistical analysis | Clinical trials | Cardiovascular disease | Blood pressure | Statistical methods | Data bases | Index Medicus | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights